IRLAB Therapeutics, a Swedish Parkinson's disease treatment developer, will present at Life Science-dagen on March 6.

IRLAB Therapeutics, a Swedish Parkinson's disease treatment developer, will present at Life Science-dagen in Gothenburg on March 6. CFO Viktor Siewertz's presentation will be followed by a Q&A session and a fireside chat with ABG. IRLAB's pipeline, generated by its proprietary Integrated Screening Process (ISP), includes treatments for all stages of Parkinson's disease with several in Phase II and III trials.